中医药防治肝癌复发转移的研究进展

刘柳; 程秋骆; 白长川; 朱英

doi:10.3969/j.issn.1001-5256.2021.05.051

中医药防治肝癌复发转移的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.05.051

刘柳^{1, 2},
程秋骆^{1, 2},
白长川³,
朱英^{1, 2, ,}

1.
大连医科大学附属第一医院中西医结合肝病中心，辽宁大连 116011
2.
大连医科大学中西医结合学院，辽宁大连 116044
3.
大连市中医医院，辽宁大连 116013

基金项目:

国家自然科学基金 (81673728)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：刘柳负责文献查找与整理，并撰写初稿；程秋骆参与文献查找，提供写作意见；白长川、朱英负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
刘柳(1996—)，女，主要从事中西医防治肝病的基础和临床研究

通信作者:
朱英，zhuyingsh52@126.com

中图分类号: R735.7
计量
- 文章访问数: 1142
- HTML全文浏览量: 182
- PDF下载量: 89
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-30
- 录用日期: 2020-12-14
- 出版日期: 2021-05-20

Advances of traditional Chinese medicine in prevention and treatment of recurrence and metastasis of liver cancer

Liu LIU^{1, 2},
Qiuluo CHENG^{1, 2},
Changchuan BAI³,
Ying ZHU^{1, 2
, ,}

1.
Liver Disease Center for Combined TCM and Western Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China
2.
Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, Liaoning 116044, China
3.
Dalian Hospital of Traditional Chinese Medicine, Dalian, Liaoning 116013, China

摘要

摘要: 近年来中医药防治肝癌研究取得显著进展。研究发现，中医药治疗可以通过抑制细胞增殖、诱导细胞凋亡、抑制细胞迁移侵袭、抗血管生成、调节免疫、逆转耐药等方面降低肝癌的复发转移，延长患者的生存期。总结了近10年中医药防治肝癌复发转移的临床与基础研究，认为中医药对肝癌复发转移防治具有低毒性、多靶点、多途径优势。在日后的研究中，应重点着眼于如何筛选出作用于肝癌的有效成分，了解中药的完整作用机制，能否保障体内外验证中药疗效的一致性，以及临床多中心研究药物对于不同地区人群的作用是否存在差异性等方面。
- 肝肿瘤 /
- 中医疗法 /
- 复发 /
- 肿瘤转移
Abstract: Great achievements have been made in traditional Chinese medicine in the prevention and treatment of liver cancer in recent years. Studies have shown that traditional Chinese medicine can reduce the recurrence and metastasis of liver cancer and prolong the survival time of patients by inhibiting cell proliferation, inducing cell apoptosis, inhibiting cell migration and invasion, inhibiting angiogenesis, regulating immunity, and reversing drug resistance. This article reviews the clinical and basic studies on the effect of traditional Chinese medicine in the prevention and treatment of recurrence and metastasis of liver cancer in the recent 10 years, and it is believed that traditional Chinese medicine has the advantages of low toxicity, multiple targets, and multiple pathways in the prevention and treatment of recurrence and metastasis of liver cancer. Future research should focus on how to screen out the effective constituents for liver cancer, how to understand the complete mechanism of action of traditional Chinese medicine, whether the consistency in the efficacy of traditional Chinese medicine between in vivo and in vitro studies can be guaranteed, and whether there is a difference in the role of investigational drugs between populations from different regions in multicenter clinical studies.
- Liver Neoplasms /
- TCM Therapy /
- Recurrence /
- Neoplasm Metastasis

HTML全文

参考文献(49)

[1]	YAMASHITA Y, YOSHIDA Y, KURIHARA T, et al. Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: Repeat hepatectomy versus salvage living donor liver transplantation[J]. Liver Transpl, 2015, 21(7): 961-968. DOI: 10.1002/lt.24111.
[2]	ZHANG CA, GU YF, ZHANG YC, et al. Discussion on clinical thoughts for treating liver cancer recurrence and metastasis from phlegm[J]. J Oncol Tradit Chin Med, 2020, 2(1): 31-35. DOI: 10.19811/j.cnki.ISSN2096-6628.2020.01.008. 张慈安, 顾雨芳, 张映城, 等. 浅析从痰论治肝癌复发转移的临床思路[J]. 中医肿瘤学杂志, 2020, 2(1): 31-35. DOI: 10.19811/j.cnki.ISSN2096-6628.2020.01.008.
[3]	ZHAI XF, LIU XL, SHEN F, et al. Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study[J]. Cancer, 2018, 124(10): 2161-2168. DOI: 10.1002/cncr.30915.
[4]	ZHAI XF, CHEN Z, LI B, et al. Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: A multicenter randomized controlled trial[J]. J Integr Med, 2013, 11(2): 90-100. DOI: 10.3736/jintegrmed2013021.
[5]	CHEN Z, CHEN HY, LANG QB, et al. Preventive effects of jiedu granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial[J]. Chin J Integr Med, 2012, 18(5): 339-344. DOI: 10.1007/s11655-012-1083-1.
[6]	CHEN ZY, LIANG J, DENG X. Effectiveness of integrative medicine for preventing postoperative recurrence of primary hepatic carcinomas: A systematic review[J]. Chin J Integr Med, 2014, 34(6): 671-675. DOI: 10.7661/CJIM.2014.06.0671. 陈子瑶, 梁健, 邓鑫. 中西医结合预防原发性肝癌术后复发作用的系统评价[J]. 中国中西医结合杂志, 2014, 34(6): 671-675. DOI: 10.7661/CJIM.2014.06.0671.
[7]	WAN YM, LI YH, XU ZY, et al. The effect of transarterial chemoembolization in combination with Kang'ai injection on patients with intermediate stage hepatocellular carcinoma: A prospective study[J]. Integr Cancer Ther, 2018, 17(2): 477-485. DOI: 10.1177/1534735417734913.
[8]	SUN Z, LIANG ST, ZHAI XF, et al. A traditional Chinese herbal medicine compound preparation versus interventional therapy after resection of small hepatocellular carcinoma: 22-year follow-up[J]. J Tradit Chin Med, 2012, 32(2): 156-163. DOI: 10.1016/s0254-6272(13)60005-9.
[9]	ZHONG C, HU ML, HUANG JH, et al. Clinical study of Jianpi Huayu method combined with TACE in the treatment of postoperative recurrence of liver cancer[J]. New J Tradit Chin Med, 2016, 48(5): 208-210. DOI: 10.13457/j.cnki.jncm.2016.05.080. 钟崇, 胡明利, 黄俊海, 等. 健脾化瘀法中药联合TACE治疗肝癌术后复发临床研究[J]. 新中医, 2016, 48(5): 208-210. DOI: 10.13457/j.cnki.jncm.2016.05.080.
[10]	WU SY, CHEN Y, ZHOU HQ, et al. Clinical observation of Ling Yaoxing's academic experience in anti recurrence and metastasis of liver cancer after interventional therapy[J]. J Tradit Chin Med Lit, 2012, 3: 42-44. DOI: 10.3969/j.issn.1006-4737.2012.03.016. 吴士延, 陈越, 周惠清, 等. 凌耀星学术经验应用于肝癌介入术后抗复发转移的临床观察[J]. 中医文献杂志, 2012, 3: 42-44. DOI: 10.3969/j.issn.1006-4737.2012.03.016.
[11]	LIU Y, NI JF, YIN XZ, et al. Effects of Xiao'aiping injection on the serum tumor markers of patients with hepatocellular carcinoma[J]. Anti-Tumor Pharm, 2017, 7(1): 83-86. DOI: 10.3969/j.issn.2095-1264.2017.01.17. 刘源, 倪渐凤, 尹先哲, 等. 消癌平注射液对肝癌患者血清肿瘤标志物水平的影响[J]. 肿瘤药学, 2017, 7(1): 83-86. DOI: 10.3969/j.issn.2095-1264.2017.01.17.
[12]	HAO CH, TIAN LB, HE J. The prophylactic effect and survival function of compound kushen injection on postoperative recurrence of primary liver cancer[J]. Chin J Integr Tradit West Med Liver, 2020, 30(4): 303-306. DOI: 10.3969/j.issn.1005-0264.2020.04.005. 郝春海, 田立斌, 何津. 复方苦参注射液对原发性肝癌患者术后复发的预防作用及生存函数分析[J]. 中西医结合肝病杂志, 2020, 30(4): 303-306. DOI: 10.3969/j.issn.1005-0264.2020.04.005.
[13]	ZHAO N. Clinical observation on therapeutic effect of single ganoderma applanatum decoction combined with transhepatic arterial[J]. Harbin Med J, 2015, 3: 231-233, 234. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYY201503030.htm 赵娜. 单味树舌煎剂联合TACE对肝癌术后复发患者治疗效果的临床观察[J]. 哈尔滨医药, 2015, 3: 231-233, 234. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYY201503030.htm
[14]	GU W, CAI B, WU MY, et al. TACE combined with compound Taxus capsule in preventing recurrence of liver cancer after operation[J]. J Hepatopancreatobiliary Surg, 2015, 27(4): 339-341. DOI: 10.11952/j.issn.1007-1954.2015.04.025. 顾炜, 蔡兵, 吴鸣宇, 等. TACE联合复方红豆杉胶囊对预防肝癌术后复发的研究[J]. 肝胆胰外科杂志, 2015, 27(4): 339-341. DOI: 10.11952/j.issn.1007-1954.2015.04.025.
[15]	LING CQ, YUE XQ, LING C. Three advantages of using traditional Chinese medicine to prevent and treat tumor[J]. J Integr Med, 2014, 12(4): 331-335. DOI: 10.1016/S2095-4964(14)60038-8.
[16]	LIANG SF, LIU D, CHENG BB. Experimental study progress of chinese herbal compound on treating primary liver cancer[J]. J Liaoning Univ Tradit Chin Med, 2017, 19(8): 152-155. DOI: 10.13194/j.issn.1673-842x.2017.08.044. 梁淑芳, 刘栋, 程彬彬. 中药复方治疗原发性肝癌实验研究进展[J]. 辽宁中医药大学学报, 2017, 19(8): 152-155. DOI: 10.13194/j.issn.1673-842x.2017.08.044.
[17]	DONG MJ, XU YQ, WAN Z. Experimental research progress on the mechanism of Chinese herbal compound in treatment of liver cancer[J]. Glob Tradit Chin Med, 2017, 10(10): 1170-1173. DOI: 10.3969/j.issn.1674-1749.2017.10.036. 董孟佳, 许尤琪, 万祯. 中药复方治疗肝癌机理的实验研究进展[J]. 环球中医药, 2017, 10(10): 1170-1173. DOI: 10.3969/j.issn.1674-1749.2017.10.036.
[18]	LI Y, WANG HY, WU DP, et al. Antitumor effects of Polyphylla saponins Ⅰ on hepatocellular carcinoma cells based on epigenetic regulation of TRB3[J]. Mod Digest Interv, 2019, 24(9): 980-983, 988. DOI: 10.3969/j.issn.1672-2159.2019.09.009. 李杨, 汪翰英, 吴大鹏, 等. 基于TRB3基因调控探讨重楼皂苷Ⅰ抑制肝癌细胞增殖的研究[J]. 现代消化及介入诊疗, 2019, 24(9): 980-983, 988. DOI: 10.3969/j.issn.1672-2159.2019.09.009.
[19]	LI YM, LI XJ. Effect of total flavonoids of verbena officinalis on IL-6、JAK2、STAT3 level of human hepatocellular carcinoma HepG-2 cells[J]. J Henan Univ Sci & Techno (Med Sci), 2017, 35(3): 169-171. DOI: 10.15926/j.cnki.issn1672-688x.2017.03.003. 李永明, 李先佳. 马鞭草总黄酮对肝癌HepG-2细胞IL-6、JAK2、STAT3水平的影响[J]. 河南科技大学学报(医学版), 2017, 35(3): 169-171. DOI: 10.15926/j.cnki.issn1672-688x.2017.03.003.
[20]	ZHANG B, XU CJ, ZHA FF, et al. Effects of Jianpi Jiedu herbs on proliferation of HepG2 cells and the expression of PI3K and AKT[J]. J Chin Med Pharm, 2019, 47(3): 23-26. DOI: 10.19664/j.cnki.1002-2392.190072. 张斌, 徐春江, 查芳芳, 等. 健脾解毒中药对肝癌HepG2细胞增殖及PI3K、AKT表达的影响[J]. 中医药学报, 2019, 47(3): 23-26. DOI: 10.19664/j.cnki.1002-2392.190072.
[21]	YAN XY, LI J, LIN CJ, et al. Experimental study of in-vitro effects of SiJunZi decoction joined with GeXia ZhuYu decoction on human liver cell line HepG2 and SMMC[J]. West J Tradit Chin Med, 2019, 32(4): 12-15. DOI: 10.3969/j.issn.1004-6852.2019.04.004. 闫向勇, 李俊, 蔺彩娟, 等. 四君子汤合膈下逐瘀汤对人肝癌细胞株HepG2和SMMC体外作用的实验研究[J]. 西部中医药, 2019, 32(4): 12-15. DOI: 10.3969/j.issn.1004-6852.2019.04.004.
[22]	HAN ZW, WANG ZY, JU JN, et al. Regulatory effect of water extract of Jianpi Xiaoji prescription on autophagy of human liver cancer SMMC7721 cells[J]. J Clin Hepatol, 2020, 36(3): 587-591. DOI: 10.3969/j.issn.1001-5256.2020.03.023. 韩志伟, 王宗玉, 鞠佳霓, 等. 健脾消积方水提物对人肝癌SMMC7721细胞自噬的调控机制[J]. 临床肝胆病杂志, 2020, 36(3): 587-591. DOI: 10.3969/j.issn.1001-5256.2020.03.023.
[23]	WANG K, WANG YY, YANG M, et al. Influence of Jiawei Xiaoyaosan on hepatoma cell apoptosis and calcium[J]. J Anhui Med Univ, 2019, 54(2): 272-276. DOI: 10.19405/j.cnki.issn1000-1492.2019.02.022. 王昆, 王瑶瑶, 杨茂, 等. 加味逍遥散对肝癌细胞凋亡及钙离子的影响[J]. 安徽医科大学学报, 2019, 54(2): 272-276. DOI: 10.19405/j.cnki.issn1000-1492.2019.02.022.
[24]	LIN Y, LAI WF, LI CC, et al. The liver-protecting function and mechanism of Pien Tze Huang on H22 hepatocellular carcinoma ascites mice based on ANXA1/VEGF signaling pathway[J]. Fujian J Tradit Chin Med, 2020, 51(1): 37-40. https://www.cnki.com.cn/Article/CJFDTOTAL-FJZY202001013.htm 林雅, 赖文芳, 李聪翀, 等. 基于ANXA1/VEGF通路研究片仔癀对肝癌腹水小鼠的保护作用[J]. 福建中医药, 2020, 51(1): 37-40. https://www.cnki.com.cn/Article/CJFDTOTAL-FJZY202001013.htm
[25]	LAI WF, HUANG X, LIU JJ, et al. Pien Tze Huang promotes HepG2 apoptosis via regulating ANXA1/VEGF signaling pathway[J]. Chin Pharmacol Bull, 2019, 35(11): 1534-1538. DOI: 10.3969/j.issn.1001-1978.2019.11.011. 赖文芳, 黄鑫, 刘俊杰, 等. 片仔癀调控膜联蛋白A1/VEGF通路对人肝癌细胞系HepG2作用的影响[J]. 中国药理学通报, 2019, 35(11): 1534-1538. DOI: 10.3969/j.issn.1001-1978.2019.11.011.
[26]	HAN K, BAO YR, WANG S, et al. Inhibitory effect and mechanism study of Chinese medicinal sanguisorba offcinalis L. in human hepatocellular carcinoma cell line HepG2[J]. J Liaoning Univ Tradit Chin Med, 2019, 21(5): 30-32. DOI: 10.13194/j.issn.1673-842x.2019.05.008. 韩康, 包永睿, 王帅, 等. 中药地榆对肝癌HepG2细胞的抑制作用及机制研究[J]. 辽宁中医药大学学报, 2019, 21(5): 30-32. DOI: 10.13194/j.issn.1673-842x.2019.05.008.
[27]	YANG JB, LI HJ. Effects of matrine and oxymatrine matrine on proliferation and apoptosis of hepatocellular carcinoma cells[J]. Chin J Clin Pharmacol, 2018, 34(9): 1067-1069. DOI: 10.13699/j.cnki.1001-6821.2018.09.017. 杨静波, 李宏杰. 苦参碱和氧化苦参碱对肝癌细胞增殖和凋亡的影响[J]. 中国临床药理学杂志, 2018, 34(9): 1067-1069. DOI: 10.13699/j.cnki.1001-6821.2018.09.017.
[28]	LIU M, XIONG CM, WANG ZY, et al. Effect of tanshinone Ⅱ A on phosphorylation of Smad3/Smad7 protein and epithelial mesenchymal transition of hepatocellular carcinoma cell line MHCC97-H[J]. Guid J Tradit Chin Med Pharmacol, 2017, 23(10): 30-34. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZB201710011.htm 刘敏, 熊成名, 王子豫, 等. 丹参酮ⅡA对肝癌细胞MHCC97-H Smad3/Smad7蛋白及上皮间质转化的影响[J]. 中医药导报, 2017, 23(10): 30-34. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZB201710011.htm
[29]	HE WB, SU RJ. Pulsatilla saponin D combined with sorafenib against hepatocellular carcinoma cell invasion and metastasis[J]. J Shandong Univ (Med), 2016, 54(7): 18-22. DOI: 10.6040/j.issn.1671-7554.0.2015.610. 贺武斌, 苏荣健. 白头翁皂苷D联合索拉非尼对人肝癌细胞侵袭与转移的影响[J]. 山东大学学报(医学版), 2016, 54(7): 18-22. DOI: 10.6040/j.issn.1671-7554.0.2015.610.
[30]	LIU J, WEN X, LIU B, et al. Diosmetin inhibits the metastasis of hepatocellular carcinoma cells by downregulating the expression levels of MMP-2 and MMP-9[J]. Mol Med Rep, 2016, 13(3): 2401-2408. DOI: 10.3892/mmr.2016.4872.
[31]	LIN W, ZHONG M, LIANG S, et al. Emodin inhibits migration and invasion of MHCC-97H human hepatocellular carcinoma cells[J]. Exp Ther Med, 2016, 12(5): 3369-3374. DOI: 10.3892/etm.2016.3793.
[32]	CHIEN ST, SHI MD, LEE YC, et al. Galangin, a novel dietary flavonoid, attenuates metastatic feature via PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells[J]. Cancer Cell Int, 2015, 15: 15. DOI: 10.1186/s12935-015-0168-2.
[33]	LI YY, WEI ZH, ZHONG QH, et al. Effect of Chinese medicine cinobufotalinon recurrence of hepatocellular carcinoma after TACE and expression of VEGF/TSGF in serum[J]. Liaoning J Tradit Chin Med, 2020, 47(1): 131-134. DOI: 10.13192/j.issn.1000-1719.2020.01.043. 李岳勇, 韦忠恒, 钟秋红, 等. 中药华蟾素对肝细胞肝癌TACE术后肝内复发和血清VEGF/TSGF表达的影响[J]. 辽宁中医杂志, 2020, 47(1): 131-134. DOI: 10.13192/j.issn.1000-1719.2020.01.043.
[34]	HU B, AN HM, WANG SS, et al. Effects and mechanism of YangGan JieDu SanJie Herbs on angiogenesis in hepatocellular carcinoma[J]. Chin J Integr Tradit West Med on Liver, 2017, 27(3): 158-160, e7. DOI: 10.3969/j.issn.1005-0264.2017.03.012. 胡兵, 安红梅, 王双双, 等. 养肝解毒散结中药对肝癌血管生成作用及机制[J]. 中西医结合肝病杂志, 2017, 27(3): 158-160, e7. DOI: 10.3969/j.issn.1005-0264.2017.03.012.
[35]	CHANG XF, ZHOU HQ, SONG CH, et al. Effect of Biejiajian Pill on VEGF/Dll4 Notch signaling pathway in human hepatoma cell line BEL-7402[J]. Jiangxi J Tradit Chin Med, 2019, 50(11): 65-67. https://www.cnki.com.cn/Article/CJFDTOTAL-JXZY201911025.htm 常欣峰, 周海倩, 宋春花, 等. 鳖甲煎丸对人肝癌细胞Bel-7402VEGF/Dll4-Notch信号通路的影响[J]. 江西中医药, 2019, 50(11): 65-67. https://www.cnki.com.cn/Article/CJFDTOTAL-JXZY201911025.htm
[36]	ZHANG YQ, WANG QT, CHEN XZ, et al. Effect of hedyotis diffusa willd on PI3K/Akt pathway in nude mice implanted hepatoma HepG2 cells[J]. J Basic Clin Oncol, 2015, 28(4): 277-280. DOI: 10.3969/j.issn.1673-5412.2015.04.001. 章尤权, 王清泰, 陈旭征, 等. 白花蛇舌草对人肝癌HepG2细胞裸鼠皮下移植瘤PI3K/Akt信号通路的影响[J]. 肿瘤基础与临床, 2015, 28(4): 277-280. DOI: 10.3969/j.issn.1673-5412.2015.04.001.
[37]	ZHANG HH, ZHANG Y, CHENG YN, et al. Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo[J]. Mol Carcinog, 2018, 57(1): 44-56. DOI: 10.1002/mc.22718.
[38]	WANG H, ZHANG C, NING Z, et al. Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling[J]. Int J Oncol, 2016, 48(3): 1229-1241. DOI: 10.3892/ijo.2016.3326.
[39]	ZHAO MH, ZHOU JN, QI Y. Mulberry polysaccharides improves the chemotherapy of liver cancer ascites tumor-bearing mice by regulating the PI3K/AKT/mTOR pathway[J]. Chin J Clin Pharmacol Ther, 2020, 25(4): 401-407. DOI: 10.12092/j.issn.1009-2501.2020.04.008. 赵妙惠, 周佳妮, 漆勇. 桑黄多糖调控PI3K/AKT/mTOR通路抑制肝癌腹水荷瘤小鼠及对化疗的减毒增效作用[J]. 中国临床药理学与治疗学, 2020, 25(4): 401-407. DOI: 10.12092/j.issn.1009-2501.2020.04.008.
[40]	CHENG XY, ZHANG Y, LU HM. Experimental study on the immunogenicity of HSP70 induced by scutellariae baicalensis on mice liver cancer H22 cells[J]. J Guangdong Med Univ, 2018, 36(6): 629-631. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYY201806007.htm 成晓燕, 张轶, 卢洪梅. 清热解毒中药黄芩诱导小鼠肝癌H22细胞HSP70免疫原性的实验研究[J]. 广东医科大学学报, 2018, 36(6): 629-631. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYY201806007.htm
[41]	YANG JB, ZHANG J, MA CZ. The clinical efficacy of Jianpifuzheng decoction and effect on immune function and quality of life in patients with terminal primary hepatoma[J]. Pharmocol Clin Chin Mater Med, 2017, 33(4): 163-166. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYL201704046.htm 杨静波, 张娟, 马纯政. 健脾扶正汤对晚期原发性肝癌患者临床疗效及免疫功能、血清肿瘤标志物的影响[J]. 中药药理与临床, 2017, 33(4): 163-166. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYL201704046.htm
[42]	ZHOU N, JI R, ZHANG YJ, et al. Effects of Chinese medicine prescription on blood glucose and immune function of patients with primary liver cancer complicated with type 2 diabetes[J]. China Pharmacist, 2019, 22(7): 1275-1277. DOI: 10.3969/j.issn.1008-049X.2019.07.021. 周宁, 冀锐, 张永静, 等. 中药方剂对合并原发性肝癌的2型糖尿病患者血糖和免疫水平影响观察[J]. 中国药师, 2019, 22(7): 1275-1277. DOI: 10.3969/j.issn.1008-049X.2019.07.021.
[43]	ZHOU YD. Clinical observation of TCM syndrome differentiation combined with small dose chemotherapy in the treatment of advanced primary liver cancer[J]. Chin J Modern Appl Pharm, 2019, 13(20): 98-100. DOI: 10.14164/j.cnki.cn11-5581/r.2019.20.058. 周云娣. 中医辨证配合小剂量化疗治疗晚期原发性肝癌疗效观察[J]. 中国现代药物应用, 2019, 13(20): 98-100. DOI: 10.14164/j.cnki.cn11-5581/r.2019.20.058.
[44]	CHEN Y, HU H, ZHANG SJ, et al. Effect of the Sijunzi decoction on the T lymphocyte and NK cell of the hepatocellular carcinoma patients with radical operation[J]. Chin J Integr Tradit West Med on Liver, 2017, 27(1): 8-10. DOI: 10.3969/j.issn.1005-0264.2017.01.003. 陈燕, 胡浩, 张诗军, 等. 四君子汤对原发性肝癌术后患者T淋巴细胞和NK细胞的影响及意义[J]. 中西医结合肝病杂志, 2017, 27(1): 8-10. DOI: 10.3969/j.issn.1005-0264.2017.01.003.
[45]	LIANG Y, CHENG G, HUANG DG. Preventive mechanism of Yipi Huoxue recipe on postoperative recurrence for rats after hepatectomy by regulating B7-H1/PD-1 signal pathway[J]. Sichuan J Tradit Chin Med, 2019, 37(8): 24-28. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZY201908010.htm 梁颖, 程钢, 黄邓高. 益脾活血方调控B7-H1/PD-1通路对大鼠肝癌切除术后防止复发的机制研究[J]. 四川中医, 2019, 37(8): 24-28. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZY201908010.htm
[46]	HE G, CAO X, HE M, et al. Casticin inhibits self-renewal of liver cancer stem cells from the MHCC97 cell line[J]. Oncol Lett, 2014, 7(6): 2023-2028. DOI: 10.3892/ol.2014.1972.
[47]	YAO CJ, YEH CT, LEE LM, et al. Elimination of cancer stem-like "side population" cells in hepatoma cell lines by chinese herbal mixture "tien-hsien liquid"[J]. Evid Based Complement Alternat Med, 2012, 2012: 617085. DOI: 10.1155/2012/617085.
[48]	LING BF, HOU Q, ZOU X, et al. Effects of Jianpi Huayu formula on drug resistance cell P-glycoprotein in liver cancer[J]. Chin J Tradit Chin Med Pharm, 2015, 30(7): 2577-2580. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201507102.htm 凌博凡, 侯茜, 邹玺, 等. 健脾化瘀方对肝癌耐药细胞P-糖蛋白的影响[J]. 中华中医药杂志, 2015, 30(7): 2577-2580. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201507102.htm
[49]	ZHAO JY, LIU LY, ZHANG YC, et al. Xiaochaihu Tang reverses multidrug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU[J]. Pract Clin J Integr Traditl Chin West Med, 2016, 16(9): 1-3, 35. DOI: 10.13638/j.issn.1671-4040.2016.09.001. 赵锦燕, 刘丽雅, 张毓宸, 等. 小柴胡汤逆转人肝癌细胞BEL-7402/5-FU的多药耐药作用[J]. 实用中西医结合临床, 2016, 16(9): 1-3, 35. DOI: 10.13638/j.issn.1671-4040.2016.09.001.